



CLAIM AMENDMENTS

1. (original) A compound of formula **PQ**:



2. (original) A compound according to claim 1, of formula **P** or **Q**:



3. (original) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenyl]amine according to claim 1.


4. (original) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenyl]amine according to claim 1.

5. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 1 to 4.


6. (original) A tablet or capsule according to claim 5.

7. (original) A method for treating CNS disorders in a human, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (c) a mixture of **P** and **Q**; or
- (d) a pharmaceutically acceptable salt thereof.
8. (original) The method according to claim 7, wherein the CNS disorder is a mood disorder.
9. (original) The method according to claim 8; wherein the mood disorder is depression.
10. (currently amended) The method according to claim 7 8, wherein the CNS disorder is ~~an~~ anxiety-related disorder.
11. (original) The method according to claim 10, wherein the anxiety-related disorder is obsessive compulsive disorder.
12. (original) The method according to claim 7, wherein the CNS disorder is a disruptive behavior disorder.

13. (original) The method according to claim 12, wherein the disruptive behavior disorder is one of attention deficit disorder (ADD) or attention deficit / hyperactivity disorder (ADHD).

14. (original) The method according to claim 7, wherein the CNS disorder is a sexual dysfunction.


15. (original) The method according to claim 7, wherein the CNS disorder is a substance abuse disorder.

16. (original) The method according to claim 7, wherein the CNS disorder is an eating disorder.


17. (original) A method according to claim 7, wherein the CNS disorder is premenstrual syndrome disorder.

18. (original) A method for the prophylaxis of migraine in a human, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of a compound chosen from:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q**; and
- (d) a pharmaceutically acceptable salt thereof.

19. (original) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q** ; or
- (d) a pharmaceutically acceptable salt thereof, together with
- (e) a therapeutically effective amount of a D₂ antagonist, or a pharmaceutically acceptable salt thereof.


20. (original) The method according to claim 19, wherein the D₂ antagonist is olanzapine.

21. (original) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q** ; or
- (d) a pharmaceutically acceptable salt thereof, together with
- (e) a therapeutically effective amount of a typical antipsychotic agent, or a pharmaceutically acceptable salt thereof.

22. (original) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q** ; or
- (d) a pharmaceutically acceptable salt thereof, together with
- (e) a therapeutically effective amount of an atypical antipsychotic agent, or a pharmaceutically acceptable salt thereof.


23. (currently amended) A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, the process method comprising:

- (a) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone with an excess of formic acid and formamide to provide *N*-[4-(3,4-dichloro phenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide; and
- (b) hydrolyzing the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro naphthalen-1-yl]formamide with aqueous acid, yielding 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine.


24. (new) A compound of formula:




25. (new) A compound according to claim 24, of formula **E**:

**E .**

26. (new) A compound according to claim 24, of formula **F**:

**F .**

27. (new) A compound according to claim 24, of formula **A**, **B**, **C**, or **D**:



28. (new) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

29. (new) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

30. (new) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

31. (new) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.


32. (new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 24 to 31.

33. (new) A tablet or capsule according to claim 32.


34. (new) A method for treating CNS disorders in a human, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

35. (new) A method according to claim 34, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (e) a mixture of **A** and **B**;
 (f) a mixture of **C** and **D**; or
 (g) a pharmaceutically acceptable salt thereof.

36. (new) The method according to claim 34, wherein the CNS disorder is a mood disorder.


37. (new) The method according to claim 36, wherein the mood disorder is depression.
38. (new) The method according to claim 34, wherein the CNS disorder is anxiety-related disorder.
39. (new) The method according to claim 38, wherein the anxiety-related disorder is obsessive compulsive disorder.
40. (new) The method according to claim 34, wherein the CNS disorder is a disruptive behavior disorder.
41. (new) The method according to claim 40, wherein the disruptive behavior disorder is one of attention deficit disorder (ADD) or attention deficit / hyperactivity disorder (ADHD).
42. (new) The method according to claim 34, wherein the CNS disorder is a sexual dysfunction.
43. (new) The method according to claim 34, wherein the CNS disorder is a substance abuse disorder.
44. (new) The method according to claim 34, wherein the CNS disorder is an eating disorder.
45. (new) A method according to claim 34, wherein the CNS disorder is premenstrual syndrome disorder.
46. (new) A method for the prophylaxis of migraine in a human, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

47. (new) A method according to claim 46, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of a compound chosen from:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (e) a mixture of **A** and **B**;
- (f) a mixture of **C** and **D**; or
- (g) a pharmaceutically acceptable salt thereof.


48. (new) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

49. (new) A method according to claim 48, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**B ;**

- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**C ;**

- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**D ;**


- (e) a mixture of **A** and **B**;
(f) a mixture of **C** and **D**; or
(g) a pharmaceutically acceptable salt thereof, together with
(h) a therapeutically effective amount of a D₂ antagonist, or a pharmaceutically acceptable salt thereof.

50. (new) The method according to claim 48, wherein the D₂ antagonist is olanzapine.


51. (new) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

52. (new) A method according to claim 51, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



C ;

- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




D ;

- (e) a mixture of **A** and **B**;
 (f) a mixture of **C** and **D**; or
 (g) a pharmaceutically acceptable salt thereof, together with
 (h) a therapeutically effective amount of a typical antipsychotic agent, or a pharmaceutically acceptable salt thereof.


53. (new) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

54. (new) A method according to claim 53, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (e) a mixture of **A** and **B**;
- (f) a mixture of **C** and **D**; or
- (g) a pharmaceutically acceptable salt thereof, together with
- (h) a therapeutically effective amount of an atypical antipsychotic agent, or a pharmaceutically acceptable salt thereof.

55. (new) A process for preparing *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide comprising reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone with an excess of formic acid and formamide to provide *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

56. (new) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is of the (*S*) configuration and the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide is a 1:1 mixture of (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

57. (new) The process according to claim 56, further comprising separating the (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide.

58. (new) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is of the (*R*) configuration and the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide is a 1:1 mixture of (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

59. (new) The process according to claim 58, further comprising separating the (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide.

60. (new) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is racemic and the process further comprises separating the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide into *cis N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and *trans N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.